Skip to main content
. Author manuscript; available in PMC: 2022 Nov 2.
Published in final edited form as: Antiviral Res. 2018 Apr 27;155:12–19. doi: 10.1016/j.antiviral.2018.04.019

Fig. 3. Mutations in the DENV capsid confer resistance to VGTI-A3.

Fig. 3.

(A) Virus was passaged 4 times in the presence of 1uM VGTI-A3 at MOI = 0.1ffu/cell on HEK293 cells. Virus was assayed for resistance at each passage, and RNA isolated from p4 virus was sequenced by Sanger sequencing. (B) Region of the DENV2 C protein (residues 20–40) with mutations (red) found in resistant virus populations and corresponding region of related flaviviruses, DENV1–4 and WNV. (C) Mutations were introduced into the DENV2 16681 infectious clone, and resultant viruses were assayed for resistance by infection of HEK293 at MOI = 0.1 ffu/cell in the presence of 30 nM-10μM VGTI-A3. Infectious virus present in the supernatants collected at 3 days p.i. was quantitated by focus forming assay. Data are presented as mean ± SEM in triplicate. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)